Skip to main content

Table 4 Change from baseline in trough FEV1 (mL), according to patient withdrawal, during the 1-year treatment period

From: Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Trough FEV1 (mL), LS mean (SE)

Revefenacin 88 μg

Revefenacin 175 μg

Tiotropium 18 μg

Day 29 and still on study at Day 92

88.8 (9.63)

n = 278

121.8 (11.10)

n = 232

113.7 (8.64)

n = 296

Day 92 and still on study at Day 183

84.5 (10.74)

n = 236

100.8 (11.78)

n = 203

104.7 (8.88)

n = 275

Day 183 and still on study at Day 274

73.1 (11.50)

n = 216

98.9 (12.27)

n = 182

94.4 (9.13)

n = 259

Day 274 and still on study at Day 365

68.3 (11.46)

n = 207

65.6 (11.71)

n = 181

86.1 (9.21)

n = 242

Day 29 and withdrew prior to Day 92

73.4 (19.25)

n = 39

130.8 (15.48)

n = 50

130.8 (21.37)

n = 34

Day 92 and withdrew prior to Day 183

93.1 (19.21)

n = 51

97.3 (26.50)

n = 40

42.7 (25.92)

n = 32

Day 183 and withdrew prior to Day 274

99.4 (33.22)

n = 23

137.2 (34.49)

n = 28

143.5 (32.19)

n = 24

Day 274 and withdrew prior to Day 365

83.4 (55.68)

n = 16

60.0 (106.42)

n = 8

57.0 (36.85)

n = 23

  1. FEV1 forced expiratory volume in 1 s, LS least squares, SE standard error